Suntech Medical announced that its product Isavuconazonium Sulfate for Injection and the co-developed product Enzalutamide Tablets have been tentatively selected in the 12th National Centralized Drug Procurement. Isavuconazonium Sulfate for Injection is indicated for invasive aspergillosis and invasive mucormycosis, with the tentatively selected specification being one vial per box. Enzalutamide Tablets are indicated for prostate cancer-related conditions, with tentatively selected specifications including 40-milligram packs of 56 tablets and 80-milligram packs of 28 tablets. The procurement cycle runs from the implementation date of the selection results until December 31, 2029, during which medical institutions will prioritize the use of the winning drugs and ensure the fulfillment of agreed procurement volumes. The company stated that if subsequent procurement contracts are signed and implemented, it will help expand product sales scale, increase market share, and promote the development of the domestic market.
Sinotherapeutics Inc. AProducts tentatively selected in national procurement, expanding sales and market share.